MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis

• Main Authors: Benner, Axel, Mansouri, Larry, Rossi, Davide, Majid, Aneela, Willander, Kerstin, Parker, Anton, Bond, Gareth, Pavlova, Sarka, Nückel, Holger, Merkel, Olaf, Ghia, Paolo, Montserrat, Emili, Kaderi, Mohd Arifin, Rosenquist, Richard, Gaidano, Gianluca, Dye, Martin J.S., Söderkvist, Peter, Linderholm, Mats, Oscier, David, Tvaruzkova, Zuzana, Pospisilova, Sarka, Dührse, Ulrich, Greil, Richard, Döhner, Hartmut, Stilgenbauer, Stephan, Zenz, Thorsten
• Format: Article
• Language: English; English; English
• Published: Ferrata Storti Foundation 2014
• Subjects: Q Science (General); RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://irep.iium.edu.my/38695/1/MDM_Arifin_2014_Haematologica.pdf; http://irep.iium.edu.my/38695/4/38695_MDM2%20promotor%20polymorphism%20and%20disease%20characteristics%20in%20chronic%20lymphocytic%20leukemia_SCOPUS.pdf; http://irep.iium.edu.my/38695/5/38695_MDM2%20promotor%20polymorphism%20and%20disease%20characteristics%20in%20chronic%20lymphocytic%20leukemia_WoS.pdf; http://irep.iium.edu.my/38695/; https://pubmed.ncbi.nlm.nih.gov/25082786/

A number of single nucleotide polymorphisms have been associated with disease predisposition in chronic lympho- cytic leukemia. A single nucleotide polymorphism in the MDM2 promotor region, MDM2SNP309, was shown to soothe the p53 pathway. In the current study, we aimed to clarify the effect of the M...